Ainos Inc
NASDAQ:AIMD
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.64
4.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Ainos Inc
Ainos, Inc. engages in the discovery and development of pharmaceutical and biotech products. The company is headquartered in San Diego, California and currently employs 34 full-time employees. The firm is researching for the treatment of human disease indications, including Sjogren’s syndrome, thrombocytopenia, and other indications using interferon-alpha. The firm is also developing and manufacturing point-of-care testing rapid test kit products that include diagnostics for COVID-19, pneumonia, vaginal infection and helicobacter pylori bacterial infection. Its business units include Pharmaceutical, Medical Devices and Preventive Medicine Divisions. Pharmaceutical Division is focused on low-dose, orally administered lozenges containing the natural immune system activator interferon-alpha as a treatment for a variety of disease indications. Medical Device Division is developing an insulin pump and further development of point-of-care rapid test kits for the detection and diagnosis of human infections. Preventative Medicine Division is focused on SRNA-based therapeutics.
Ainos, Inc. engages in the discovery and development of pharmaceutical and biotech products. The company is headquartered in San Diego, California and currently employs 34 full-time employees. The firm is researching for the treatment of human disease indications, including Sjogren’s syndrome, thrombocytopenia, and other indications using interferon-alpha. The firm is also developing and manufacturing point-of-care testing rapid test kit products that include diagnostics for COVID-19, pneumonia, vaginal infection and helicobacter pylori bacterial infection. Its business units include Pharmaceutical, Medical Devices and Preventive Medicine Divisions. Pharmaceutical Division is focused on low-dose, orally administered lozenges containing the natural immune system activator interferon-alpha as a treatment for a variety of disease indications. Medical Device Division is developing an insulin pump and further development of point-of-care rapid test kits for the detection and diagnosis of human infections. Preventative Medicine Division is focused on SRNA-based therapeutics.